Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.

Original languageEnglish (US)
Pages (from-to)995-1004
Number of pages10
JournalMayo Clinic Proceedings
Volume92
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Glioma
Precision Medicine
Immunotherapy
Neoplasms
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of Glioma in the 21st Century : An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. / Uhm, Joon H.; Porter Umphrey, Alyx B.

In: Mayo Clinic Proceedings, Vol. 92, No. 6, 01.06.2017, p. 995-1004.

Research output: Contribution to journalReview article

@article{b9ef7b725a9e470d8be69b77c8d4fb07,
title = "Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era",
abstract = "The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.",
author = "Uhm, {Joon H.} and {Porter Umphrey}, {Alyx B}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.mayocp.2017.01.010",
language = "English (US)",
volume = "92",
pages = "995--1004",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Treatment of Glioma in the 21st Century

T2 - An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era

AU - Uhm, Joon H.

AU - Porter Umphrey, Alyx B

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.

AB - The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.

UR - http://www.scopus.com/inward/record.url?scp=85026318645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026318645&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.01.010

DO - 10.1016/j.mayocp.2017.01.010

M3 - Review article

C2 - 28578786

AN - SCOPUS:85026318645

VL - 92

SP - 995

EP - 1004

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -